16th & 17th NovemberManchester, UK

Posters

Posters

Posters

Please contact Bio2Business for pricing details should you wish to showcase your ePoster.


Featured posters from BOS 2019

Drug Product : Small Molecules

Acino CMO specific technology capabilities

PDF for Acino International
Company
Acino International
More information
Alina Simonenko
Keywords
Acino CMO specific technology capabilities for OSD

Download PDF

For many decades, Acino has been mastering the manufacturing of pharmaceuticals and gained in-depth knowledge in the processing of oral solid dosage forms (granulate, pellets, tablets & capsules). This poster provides an overview of the specific Acino CMO technology capabilities for oral solid dosage forms and services.

Drug Substance : Biologics

Application of MVDA, Raman Spectroscopy and Process Control to enhance bioprocess understanding

PDF for APC Ltd.
Company
APC Ltd.
More information
David Crowley
Keywords
MVDA, Raman Spectroscopy, Process Control, Process Development

Download PDF

Chinese Hamster Ovary cells are the most widely-used platform for the production of monoclonal antibodies (mAbs) by the biopharmaceutical sector. CHO cell mAb manufacturing processes require refinement to ensure that the highest product yield is achieved while ensuring quality. The use of Process Analytical Technology (PAT), such as Raman spectroscopy, enables in-depth interrogation of cell culture operations in order to define optimal feeding and control strategies.

Drug Substance : Small Molecules

Innovation in Flow Chemistry for Accelerating the Critical Path to First-in-Human Trials

PDF for Arcinova
Company
Arcinova
More information
Paul Quigley
Keywords
Innovation, Flow Technology, Drug Substance, Drug Product, Scalability, Biotech

Download PDF

There is an urgent market need for an integrated drug substance / drug product offering using one site and with an intensive technology focus. The new Arcinova model ensures secure delivery of technically complex projects with a focus on velocity and scalability. Rapid delivery of materials to Biotech clients is a key differentiator and aligns with the Biotech fundraising model, which is highly focused on clinical deliverables and payment milestones.

Discovery : Small Molecules

Ardena services

PDF for Ardena
Company
Ardena
More information
Joren De Koning
Keywords
Drug Substance, Drug Product, Solid State Research, API, Nanomedicines, Clinical Supply, Bioanlysis, Regulatory Dossier Development

Download PDF

Ardena offers an integrated, flexible service encompassing drug substance production, dosage form manufacture, clinical logistics, bioanalysis and dossier development. We are also at the leading edge of nanomedicine development. Our precision particle engineering and characterisation technologies are the key to accessing this fast evolving, competitive market.

Drug Substance : Small Molecules

Continuous Production of Anhydrous tert-Butyl Hydroperoxide in Nonane Using Membrane Pervaporation and Its Application in Flow Oxidation of a γ-Butyrolactam

PDF for Asymchem Laboratories (Tianjin) Co Ltd
Company
Asymchem Laboratories (Tianjin) Co Ltd
More information
Jordi Robinson
Keywords
Flow chemistry, Membrane pervaporation, Oxidation, Continuous process, Continuous extraction, Diastereoselective synthesis, Continuous concentration, End-to-end, Power Of Flow

Download PDF

Anhydrous tert-butyl hydroperoxide (TBHP) is a powerful oxidizing agent in many chemical transformations. Despite its versatility, the use of anhydrous TBHP has been greatly limited because of safety concerns, particularly on a production scale. We describe a membrane pervaporation method that allows the production of anhydrous TBHP solution in continuous manner. The system consists of membrane modules in series that are made of perfluorinated polymer, allowing it to remove water efficiently.

Drug Substance : Small Molecules

Locating and understanding hydrated forms of an API

PDF for Cambrex
Company
Cambrex
More information
Keywords

Download PDF

Facile hydrate formation can drastically alter the processability, stability and aqueous solubility of a given API. Cambrex Edinburgh was able to fully characterize and develop a reliable method for avoiding the hemi-hydrated form of an API that was discovered during a polymorph screening project.

Discovery : Small Molecules

Capture Compound Mass Spectrometry®: on- and off-target deconvolution

PDF for Charles River
Company
Charles River
More information
Tammy Ladduwahetty
Keywords
target, deconvolution, toxicity

Download PDF

Capture Compound Mass Spectrometry(CCMS) is an unbiased, proteome-wide approach for the identification of specific-binding protein targets for small molecules and peptides. The technology combines medicinal chemistry and in vitro pharmacology, coupled to high resolution proteomics mass spectrometry to isolate and identify target proteins that are responsible for an observed biological response. This technology can be used in a variety of contexts from target de-convolution and drug re-purposing.

Discovery : Other

INOFEA Poster BOS 2019

PDF for INOFEA AG
Company
INOFEA AG
More information
Dr. Yves Dudal
Keywords
empowered enzymes, bioanalysis, bioconjugation, biocatalysis

Download PDF

Drug Product : Biologics

This is not just fill finish: insight from a C(D)MO perspective

PDF for Legacy Pharmaceuticals Switzerland GmbH
Company
Legacy Pharmaceuticals Switzerland GmbH
More information
Carole Delauney
Keywords
sterile aseptic fill finish contract manufacturing

Download PDF

After a long and expensive process to develop DS, biotech companies want to quickly move to First-in-Human. The added value of Fill Finish is often regarded as a simple development step, but it is actually extremely complex in nature. Not enough time for Fill Finish partners selection and technology transfer is usually planned, as well as for primary packaging selection. The establishment of a strong Fill Finish partners network early in the process could save time and money in DP developments.

Discovery : Small Molecules

Development of an early wound model in human ex vivo skin explant as a preclinical model of wound healing

PDF for MedPharm
Company
MedPharm
More information
Daniel Morland
Keywords
Wound Healing, Model, Ex Vivo, Skin, Pre-Clinical

Download PDF

This assay has the potential to be used as an early screening tool for drug selection and topical formulation optimisation for NCE and generic medicine development for the advanced healing of wounded skin. Whether targeting keratinocyte proliferation and differentiation, modulation of inflammatory response, or collagen and fibroblast remodeling, this model has the potential for proof of concept research in the dermatological advancement of topical wound therapies.

Discovery : Small Molecules

The development of a set of novel small molecule inhibitors of the Kv1.3 ion channel

PDF for Metrion Biosciences
Company
Metrion Biosciences
More information
Sophie Rose
Keywords
small molecules; ion channels; potassium channels; drug discovery; auto-immune disease

Download PDF

Ion channels represent 15-20% of historic drug approvals but are notoriously complex targets and require specialised screening technology such as automated patch clamp (APC) electrophysiology. We outline a situation where a pharma company turns to a specialist CRO to fill their knowledge gap. During the collaboration, we developed potent and selective Kv1.3 modulators with nM efficacy against human T-cells and potential to treat auto-immune disease.

Drug Substance : Small Molecules

CESS for the Production of Nanoparticles

PDF for Nanoform Finland
Company
Nanoform Finland
More information
Niklas Sandler
Keywords
Nanoparticles, nanonisation

Download PDF

The patented CESS technology is based on supercritical CO2. The drug solution is expanded through a controlled process to produce pure drug nanoparticles. In this poster we show our nanonisation approach and a few case studies of nanoparticle production for tuning the particle size of APIs.

Drug Product : Other

Demand for Biotech packaging drives significant PCI investment at multiple locations world wide

PDF for PCI Pharma Services
Company
PCI Pharma Services
More information
Joanne Phelps
Keywords
Biologics, High Potent, development, clinical, manufacturing, packaging, ultra cold chain

Download PDF

PCI recognise that biologically derived therapeutic products are the new frontier, heralding revolutionary treatments of a number of diseases and injuries. We have committed to a $20m investment in support of biologic medicines and advanced injectable delivery forms. Expanding our Biotech clinical and commercial packaging and release testing capability at our Centre of Excellence in Philadelphia, as well as expanded Cold Chain capacity at numerous global locations.

Drug Substance : Small Molecules

Continuous technology improvement: key partnership to meet your outsourcing needs

PDF for Procos SpA
Company
Procos SpA
More information
Simone Manzini
Keywords
HPAPI, Flow Chemistry, API, Small Molecules

Download PDF

Procos S.p.A. is a CDMO focused to the development, scale-up and manufacturing of Active Pharmaceutical Ingredients (API’s) and has continuously expanded its technology portfolio in the last ten years in order to match customer needs. The approaches are mainly through business opportunity and customer partnership. Reported as showcases, the recent expansion into High Potent API to respond to the current market needs and the flow chemistry implementation, requested by an established customer.

Discovery : Other

Digitalisation of Research Outsourcing

PDF for scientist.com
Company
scientist.com
More information
Tom Dexter
Keywords
Outsourcing, Digitalisation, Pre-clinical, toxicology, HBS, Human Samples, Faster Science, Protein, Antibodies, Speed, Pharma, Biotech, HEOR, RWE

Download PDF

Digitalisation of business processes and drug development is a trend that will not be going away anytime soon. Scientist.com are supporting the worlds best pharma and Biotech companies to digitalise their research outsourcing processes. Creating faster science by: - Giving science time back to researchers - Removing legal delays - Accessing global innovation Real life case studies and data provide a compelling argument to transform research outsourcing.

Drug Substance : Small Molecules

Diazomethane: embracing hazardous chemistry at scale and through the utilisation of flow technology

PDF for Sterling Pharma Solutions Ltd
Company
Sterling Pharma Solutions Ltd
More information
Dr Dan Stark
Keywords
Diazomethane

Download PDF

Dr Dan Stark will be presenting Sterling Pharma Solutions capabilities for the scale-up and manufacture of complex and hazardous synthesis. Showcased through Sterling’s current work on diazomethane and the utilisation of modern flow chemistry technologies in API manufacture.

Drug Substance : Small Molecules

Development and Scale up of continuous flow processes for the manufacture of API

PDF for Thermo Fisher Scientific
Company
Thermo Fisher Scientific
More information
Peter Poechlauer
Keywords
APi, flow chemistry, continuous process

Download PDF